• Responding to email notices you receive.
    **************************************************
    In short, DON'T! Email notices are to ONLY alert you of a reply to your private message or your ad on this site. Replying to the email just wastes your time as it goes NOWHERE, and probably pisses off the person you thought you replied to when they think you just ignored them. So instead of complaining to me about your messages not being replied to from this site via email, please READ that email notice that plainly states what you need to do in order to reply to who you are trying to converse with.

  • IMPORTANT! PLEASE READ!! About the Google Adsense ads being displayed

    =====================
    Posted 08/15/2025
    =====================


    Yeah, I know. They are a pain in the butt. But they pay the bills to keep my server running. Just a fact of life, I am afraid.

    Want to get rid of them? Simple. Just become a Contributor level member or above and they will be gone. -> Please click HERE."

    Is that too much for me to ask of you to keep this site running? Well, sorry about that. I too wish I could get everything for free. But alas.....

    =====================
    Addendum: 01/10/2026
    =====================


    Google Adsense ad revenue for December, 2025 was just $30 over the cost of the lease for the server running this site. So, in effect, the money providing the incentive for me to continue running this site is coming SOLELY from the paid memberships and sponsorships here. Which honestly ain't much....

Global Snakebite Envenomation and Antivenin Report

M

Martin Nowak

Martin's Snakes
Joined
Mar 23, 2018
Messages
254
Reaction score
52
Points
28
Location
Trussville, AL
"Exact numbers can be hard to determine, but globally it’s estimated that as many as 2.7 million people are envenomed by snakes every year. Of these, up to 400,000 are permanently disabled, and estimates suggest that 81,000 to 138,000 die. Poorer nations suffer the greatest proportion of snake bites."

"The world produces less antivenom than it needs, and production quality varies. The cost to manufacture the remedy is more than most patients can afford, and anti-venom isn’t exactly a profitable business, which deters its production. And those bitten often live in remote areas where they can't access antivenom quickly."

"Development is underway for a universal snake antivenom"
Quotes Source: "Today in Science - Scientific American". 9/27/2023

Full Report:
https://www.scientificamerican.com/...tes-each-year-than-have-ever-died-from-ebola/
 
I would assume a synthetic antivenin would cost more than the real thing to manufacture. And I don't understand how you could have a "universal" antivenin? So many enzymes in each of the different types of venom, that would be a tough endeavor.
 
It would seem a tall order and complex undertaking to develop a synthetic universal antivenin. Even if one considered broad groupings such as "universal elapid" or "universal crotalid" and so forth. There are reports of successful bite treatment when species specific antivenin is unavailable but "closely related" species antivenin is available and used. I recall this among elapid envenomations.
It has been known for some years that CroFab is less effective on bites from C. helleri and C. oreganus. I don't know if these species' venom is used in production - suspect not. Here is a recent report (December 2022) indicating CroFab was not effective in treating a patient with C. helleri envenomation. Readers may also wish to look at the citations at the end of the article. Multiple reports of "how well CroFab worked on different species".
https://www.sciencedirect.com/science/article/abs/pii/S0196064422004401
 
Several years ago I was engaged to write a business plan for a VC start-up coral snake antivenin production facility. It quickly became apparent that such is enormously expensive for extremely few incidences and the notion was terminated. Plus, coral snake envenomation can be treated without antivenin.

Here is the Ophirex-BRAVO updated clinical trial link. Note that the Phase 2 trial reports completion in June 2023 with 96 of desired 110 participants. Will be interesting to read their results when available.
https://clinicaltrials.gov/study/NCT04996264

Here is the home page for Ophirex:
https://www.ophirex.com/


Here is the January 2023 Series B funding round of $37 million:
https://www.ophirex.com/20230105-ophirex-completes-37-million-series-b-financing
 
Back
Top